Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/Ib Study of Eribulin in Combination With ASTX660 (Tolinapant) in Metastatic Triple Negative Breast Cancer (TNBC)

NCT06590558 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06590558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06590558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/Ib Study of Eribulin in Combination With ASTX660 (Tolinapant) in Metastatic Triple Negative Breast Cancer (TNBC)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Withdrawn
Start date
August 4, 2025
Completion date
May 17, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, invasive breast carcinoma, locally advanced her2-negative breast carcinoma, locally advanced hormone receptor-positive breast carcinoma, locally advanced triple-negative breast carcinoma, metastatic her2-negative breast carcinoma, metastatic hormone receptor-positive breast carcinoma, metastatic triple-negative breast carcinoma, unresectable her2-negative breast carcinoma, unresectable hormone receptor-positive breast carcinoma, unresectable triple-negative breast carcinoma